The FDA approved Bayer’s asundexian, marketed as Sunharbo, for preventing recurrent ischemic strokes in eligible adults with prior non-cardioembolic ischemic stroke or high-risk transient ischemic attack. It is the first approved Factor XIa inhibitor, targeting a different coagulation mechanism from established Factor Xa inhibitors. The approval follows Phase III evidence showing reduced recurrent ischemic stroke risk, despite an earlier unsuccessful atrial-fibrillation development program. Bayer sees the medicine as an important potential growth contributor as Xarelto faces generic competition.
Reuters
Source: Reuters, November 9
Why it matters strategically
This is more than a new anticoagulant approval. It demonstrates how a drug mechanism that failed in one clinical setting can succeed in another, provided the underlying disease biology, comparator, patient population, and risk-benefit profile differ sufficiently.
For pharmaceutical developers, the implications extend to indication selection, portfolio termination criteria, and the valuation of competing Factor XIa programs.
